MediMabBio

Restoring Immune Balance

Seongnam, South Korea · Founded 2017 · $40.0M raised

Headquarters
Seongnam
Employees
11–50
Founded
2017
Business Model
B2B
Total Funding
$40.0M
Last Round
$3.0M Pre-SeedOct 2025
Rounds
3

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

MediMabBio is a biotherapeutic company focused on developing novel immunotherapies for cancer, autoimmune, and inflammatory diseases. The company's scientists — immunologists and protein engineers — use a rational design approach to engineer precision protein-based therapeutics that restore immune balance by modulating immune cell biology and signaling pathways at the molecular level. MediMabBio operates across South Korea (Pangyo/Seongnam) and the UK (Oxford BioEscalator), pursuing a flexible partnering model for out-licensing, co-development, and platform collaborations.

Summary

MediMabBio is a Biotech company based in Seongnam, South Korea, founded in 2017. It has raised $40.0M in total across 3 rounds, most recently a $3.0M Pre-Seed round in Oct 2025. Investors include Smilegate Investment, KB Investment and BNH Investment.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BOct 2025
$19.0M

Sign up to see all 3 events

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

MediMabBio on Indexed.vc
<a href="https://indexed.vc/companies/medimabbio"><img src="https://indexed.vc/api/badge/company/medimabbio" alt="MediMabBio on Indexed.vc" width="260" height="76" /></a>